Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2010 1
2012 1
2013 1
2014 2
2015 1
2016 2
2017 1
2019 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.
Hollenback D, Hambruch E, Fink G, Birkel M, Schulz A, Hornberger M, Liu K, Staiger KM, Krol HD, Deuschle U, Steeneck C, Kinzel O, Liles JT, Budas G, Watkins WJ, Kremoser C. Hollenback D, et al. Among authors: hambruch e. J Pharmacol Exp Ther. 2024 Feb 26:JPET-AR-2023-001900. doi: 10.1124/jpet.123.001900. Online ahead of print. J Pharmacol Exp Ther. 2024. PMID: 38409114 Free article.
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.
Schwabl P, Hambruch E, Budas GR, Supper P, Burnet M, Liles JT, Birkel M, Brusilovskaya K, Königshofer P, Peck-Radosavljevic M, Watkins WJ, Trauner M, Breckenridge DG, Kremoser C, Reiberger T. Schwabl P, et al. Among authors: hambruch e. Biomedicines. 2021 Jan 9;9(1):60. doi: 10.3390/biomedicines9010060. Biomedicines. 2021. PMID: 33435509 Free PMC article.
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D, Burnet M, Starlinger P, Oberhuber G, Deuschle U, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Reiberger T, Kremoser C, Trauner M. Schwabl P, et al. Among authors: hambruch e. J Hepatol. 2017 Apr;66(4):724-733. doi: 10.1016/j.jhep.2016.12.005. Epub 2016 Dec 18. J Hepatol. 2017. PMID: 27993716 Free article.
Pex5p, the peroxisomal cycling receptor, is a monomeric non-globular protein.
Costa-Rodrigues J, Carvalho AF, Fransen M, Hambruch E, Schliebs W, Sá-Miranda C, Azevedo JE. Costa-Rodrigues J, et al. Among authors: hambruch e. J Biol Chem. 2005 Jul 1;280(26):24404-11. doi: 10.1074/jbc.M501985200. Epub 2005 May 2. J Biol Chem. 2005. PMID: 15866874 Free article.
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Abel U, Schlüter T, Schulz A, Hambruch E, Steeneck C, Hornberger M, Hoffmann T, Perović-Ottstadt S, Kinzel O, Burnet M, Deuschle U, Kremoser C. Abel U, et al. Among authors: hambruch e. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4911-7. doi: 10.1016/j.bmcl.2010.06.084. Epub 2010 Jun 19. Bioorg Med Chem Lett. 2010. PMID: 20638278
Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
Kinzel O, Steeneck C, Schlüter T, Schulz A, Gege C, Hahn U, Hambruch E, Hornberger M, Spalwisz A, Frick K, Perović-Ottstadt S, Deuschle U, Burnet M, Kremoser C. Kinzel O, et al. Among authors: hambruch e. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3746-53. doi: 10.1016/j.bmcl.2016.05.070. Epub 2016 May 24. Bioorg Med Chem Lett. 2016. PMID: 27268696
12 results